Sugi Predict

Sugi Predict / Compounds / SCHEMBL220172

SCHEMBL220172

SCHEMBL220172

CC(=O)c1ccnc(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ AR P10275 4/20 0.42
▸ CA12 O43570 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ KDM4C Q9H3R0 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ KDM6B O15054 1/20 0.39
▸ TET3 O43151 1/20 0.39
▸ KDM4A O75164 1/20 0.39
▸ BBOX1 O75936 1/20 0.39
▸ KDM5A P29375 1/20 0.39
▸ KDM5C P41229 1/20 0.39
▸ ASPH Q12797 1/20 0.39
▸ KDM4D Q6B0I6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30595888 1.00 KDM1A (0.44) KDM1AHDAC1HDAC6MEN1KMT2A
Bromide SCHEMBL6203968 0.98 KDM1A (0.42) KDM1AHDAC1HDAC6MEN1KMT2A
SCHEMBL568649 0.86 KDM1A (0.41) KDM1AHDAC1HDAC6MEN1KMT2A
SCHEMBL3465859 0.83 IDO1 (0.39) KDM1AHDAC1HDAC6ARCA12
SCHEMBL28786825 0.83 LMNA (0.47) KDM1AHDAC1HDAC6MEN1KMT2A
SCHEMBL25524262 0.81 KDM1A (0.40) KDM1AHDAC1HDAC6ARCA12
SCHEMBL3124147 0.81 KDM1A (0.40) KDM1AHDAC1HDAC6ARCA12
SCHEMBL30527973 0.81 KDM4C (0.61) KDM1AHDAC1HDAC6KDM4CKDM4E
SCHEMBL40395 0.81 KDM4C (0.61) KDM1AHDAC1HDAC6KDM4CKDM4E
SCHEMBL5700471 0.79 IDO1 (0.37) KDM1AHDAC1HDAC6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 — — EP disclosed
US-20250289821-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2025-09-18 — — US disclosed
EP-3852748-B1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF LILLY CO ELI (US) 2025-09-03 — — EP disclosed
EP-4596543-A2 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Organovo, Inc. (US) 2025-08-06 — — EP disclosed
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. 2025-01-16 — — US disclosed
WO-2024261329-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 — — WO disclosed
EP-4399210-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES Black Diamond Therapeutics, Inc. (US) 2024-07-17 — — EP disclosed
EP-3356387-B1 ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS UNIV MONASH (AU) 2024-06-26 — — EP disclosed
CN-118159537-A 6-Aza-quinoline derivatives and related uses 黑钻治疗公司 2024-06-07 — — CN disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 — — US disclosed
WO-2009114552-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2009-09-17 — — WO disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 — — WO disclosed
WO-2009077990-A1 AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 — — WO disclosed
WO-2008099000-A2 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-21 — — WO disclosed
WO-2008099000-A2 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-21 — — WO disclosed
EP-1725101-A1 2-PYRIDINYL [7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A] PYRIMIDIN-3-YL] METHANONES DOV Pharmaceutical Inc. (US) 2006-11-29 — — EP disclosed
US-20050277639-A1 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones DOV PHARMACEUTICAL, INC. 2005-12-15 — — US disclosed
WO-2005084439-A1 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES DOV PHARMACEUTICAL, INC. (US) 2005-09-15 — — WO disclosed
US-5958950-A CARDIOVASCULAR DISORDERS WARNER-LAMBERT COMPANY (US) 1999-09-28 — — US disclosed
WO-1997012615-A1 BENZIMIDAZOLE DERIVATIVES AS 15-LO INHIBITORS WARNER-LAMBERT COMPANY (US) 1997-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834449-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 KDM1A 281/4885HDAC1 2265/4885HDAC6 945/4885
US-20050277639-A1 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones HTR1A, HTR2B, HTR4 KDM1A 3147/4885HDAC1 662/4885HDAC6 214/4885
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES TOP2A, TOP2B, UGT2B7 KDM1A 1076/4885HDAC1 213/4885HDAC6 114/4885
US-20250289821-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF NR1H4, NR1H2, NR1H3 KDM1A 4845/4885HDAC1 3796/4885HDAC6 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.